Lu Junmi, Feng Juan, Zheng Hongmei, Wen Qiuyuan, Fan Songqing
Department of Pathology, Second Xiangya Hospital, Central South University, Changsha 410011.
Department of Laboratory, Hunan Prevention and Treatment Institute for Occupational Diseases, Changsha 410007, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Oct 28;45(10):1149-1154. doi: 10.11817/j.issn.1672-7347.2020.190101.
To explore the expression of programmed death ligand-1 (PD-L1) as well as the correlation between the expression and the clinicopathological features or prognosis in non-small cell lung cancer (NSCLC).
The expression of PD-L1 protein in 254 cases of surgically resected lung adenocarcinoma (L-ADC), 228 cases of surgically resected lung squamous cell cancer (L-SCC), and 99 cases of non-cancerous control lung tissues was detected with immunohistochemical SP method. The correlation between the PD-L1 expression and clinicopathological features was analyzed. Kaplan-Meier univariate and Cox multivariate regression analyses were performed to assess the prognosis of patients with L-ADC and L-SCC, respectively.
Positive percentage of PD-L1 protein expression was higher in the tissues of L-ADC and L-SCC than that in the non-cancerous control lung tissues respectively (both <0.05). Positive percentage of PD-L1 protein expression was higher in the tissues of L-SCC than that in the tissues of L-ADC (<0.05). However, there were no correlation between the expression of PD-L1 and age, gender, pathological grades, clinical stages, and lymph node metastasis in L-ADC and L-SCC respectively (all >0.05). Overall survival rate was evidently lower in the L-ADC patients with positive expression of PD-L1 protein compared to the patients with negative staining of PD-L1 (<0.01). Multivariate Cox regression analysis further identified that the L-ADC patients of positive expression of PD-L1 protein had a poor prognosis (<0.01).
The positive percentage of PD-L1 protein expression is higher in the L-SCC patients than that in the L-ADC patients. Positive expression of PD-L1 protein can be served as an independent prognostic factor of poor prognosis in the patients with L-ADC.
探讨程序性死亡配体1（PD-L1）在非小细胞肺癌（NSCLC）中的表达情况及其与临床病理特征和预后的相关性。
采用免疫组织化学SP法检测254例手术切除的肺腺癌（L-ADC）、228例手术切除的肺鳞癌（L-SCC）及99例癌旁对照肺组织中PD-L1蛋白的表达。分析PD-L1表达与临床病理特征的相关性。分别进行Kaplan-Meier单因素和Cox多因素回归分析，以评估L-ADC和L-SCC患者的预后。
L-ADC和L-SCC组织中PD-L1蛋白表达阳性率分别高于癌旁对照肺组织（均P<0.05）。L-SCC组织中PD-L1蛋白表达阳性率高于L-ADC组织（P<0.05）。然而，L-ADC和L-SCC中PD-L1的表达分别与年龄、性别、病理分级、临床分期及淋巴结转移均无相关性（均P>0.05）。PD-L1蛋白表达阳性的L-ADC患者总生存率明显低于PD-L1染色阴性的患者（P<0.01）。多因素Cox回归分析进一步表明，PD-L1蛋白表达阳性的L-ADC患者预后较差（P<0.01）。
L-SCC患者中PD-L1蛋白表达阳性率高于L-ADC患者。PD-L1蛋白阳性表达可作为L-ADC患者预后不良的独立预测因素。
